Ovid Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $169 | $148 | $141 | $108 |
Gross Profit | 21 | 12 | -259 | 108,972 |
EBITDA | -20,369 | -17,281 | -17,786 | -11,626 |
EBIT | -20,517 | -17,417 | -18,188 | -12,028 |
Net Income | 8,521 | -11,694 | -15,322 | -11,252 |
Net Change In Cash | 169 | 148 | 141 | 108 |
Free Cash Flow | -14,289 | -16,705 | -11,913 | -10,056 |
Cash | 29,694 | 30,772 | 27,041 | 57,436 |
Basic Shares | 70,916 | 70,716 | 70,687 | 70,618 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $391 | $1,502 | $208,382 | $12,617 |
Gross Profit | -1,204 | 1,502 | 208,382 | 12,617 |
EBITDA | -57,684 | -54,166 | 124,447 | -81,124 |
EBIT | -59,281 | -55,548 | 124,210 | -81,430 |
Net Income | -52,338 | -51,408 | 122,834 | -80,728 |
Net Change In Cash | 391 | 1,502 | 208,382 | 12,617 |
Cost of Revenue | -142,929 | 117,694 | 30,136 | |
Free Cash Flow | -45,918 | -56,645 | 118,422 | -51,974 |
Cash | 27,041 | 129,001 | 187,797 | 72,033 |
Basic Shares | 70,580 | 70,424 | 68,067 | 58,451 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | $0.12 |
2024-03-31 | -$0.17 |
2023-12-31 | -$0.22 |
2023-09-30 | -$0.16 |
